Trinity Capital committed $12 million in growth capital to Delphinus Medical Technologies, a medical imaging company and developer of SoftVue, a dense breast screening tool for cancer detection.
The SoftVue 3D Whole Breast Ultrasound Tomography System was approved by the U.S. Food & Drug Administration (FDA) in October 2021. According to the company, 95% of women who have experienced SoftVue indicated that they would recommend the exam to other women.
“We are excited to be a part of Delphinus’ journey as they innovate life-saving medical imaging technology,” Lauren Cosentino, managing director of life sciences at Trinity Capital, said. “We believe in their team and are excited to help accelerate their growth trajectory.”
The growth capital from Trinity Capital will enable Delphinus to continue to scale operations and broaden its impact in the global healthcare community.
“Mammography is not enough to address the screening needs of dense breast patients,” Mark J. Forchette, president and CEO of Delphinus Medical Technologies, said. “The addition of SoftVue for dense breast screening implements a comprehensive solution for sites to transform the clinical experience of their patients. Our relationship with Trinity Capital helps us make impactful investments to help sites embrace this innovation and serve the unmet patient needs that SoftVue was designed to address. We are thrilled to work together.”
